Module

HBV: Why Do You Treat, Whom Do You Treat, What Are the Endpoints?

Source: Hepatitis Annual Update 2005

HBV: Why Do You Treat, Whom Do You Treat, What Are the Endpoints?


CME Program Director: Patrick J. Lynch, MD

Faculty:

Emmet B. Keeffe, MD, MACP
  • Emmet B. Keeffe, MD, MACP

CME CREDIT INFORMATION

Release Date: 11/15/05

Expiration Date: 11/14/06


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the different prophylactic and treatment approaches for various individual HBV-infected populations, including those who are HBeAg-positive vs HBeAg-negative, virally coinfected, pregnant, and immunocompromised.

  • Describe the natural history of chronic hepatitis B virus infection and factors involved in proper diagnosis.

  • Review the current and emerging treatment choices in chronic hepatitis B, including advantages and disadvantages of each treatment option.


Content includes:

  • Natural Progression of Chronic HBV Infection
  • Why Do You Treat? Cirrhosis and Hepatocellular Carcinoma
  • Whom Do You Treat?
  • How Do You Treat?
  • What Are the Endpoints?: Treatment of HBeAg-Positive Chronic Hepatitis B
  • What Are the Endpoints?: Treatment of HBeAg-Negative Chronic Hepatitis B
  • What Are the Endpoints?: Treatment of Cirrhosis in Chronic Hepatitis B Infection
  • What Are the Endpoints?: Treatment of Chronic Hepatitis B Patients Under Special Circumstances
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Pharmacist and nursing credit provided through the cosponsorship of Medical Education Collaborative and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.